Praxis Precision Medicines Advances Two NDA Reviews, Expects Dual Launches by Early 2027
The biotech's ulixacaltamide and relutrigine both cleared mid-cycle FDA reviews without advisory committee requests, positioning the company for its first commercial products.
FDA Reviews Progress Without Major Issues
Praxis Precision Medicines reported significant regulatory progress during its second quarter 2026 earnings call, with the FDA completing mid-cycle reviews for two pending new drug applications without requesting advisory committee meetings for either candidate.
For ulixacaltamide, targeting essential tremor in over 7 million Americans, CEO Marcio Souza characterized the FDA discussions as "expected and very forward-looking," noting the agency "identified no efficacy-related significant issues" (earnings call, 2026-08-06). The drug carries a January 2027 PDUFA date and would represent the first FDA-approved therapy developed specifically for essential tremor.
Relutrigine, aimed at treating severe epilepsies SCN2A and SCN8A affecting roughly 10,000 U.S. patients, received a December 27, 2026 PDUFA date after the company submitted additional sensitivity analyses that the FDA classified as a major amendment. The agency similarly confirmed it does not plan an advisory committee for this application.
Commercial Infrastructure in Place
The company has moved aggressively on commercialization preparation despite pending approvals. "Commercial leadership is in place and all core capabilities are where we expect it to be at this stage," Souza said, adding that Praxis would "be ready ahead of PDUFA to launch ulixacaltamide for ET patients" (earnings call, 2026-08-06).
COO Megan Sniecinski detailed the sales force build-out, describing recruits as "individuals with multiple launch experience, the rare neuro space, the hunters" who will execute on what she characterized as "hot launches" (earnings call, 2026-08-06). The relutrigine team is already hired and trained, while ulixacaltamide field force recruitment remains on track.
During the quarter, the FDA conducted a comprehensive BIMO inspection covering both NDA applications, examining corporate and clinical operations, safety reporting, data integrity, and statistical analysis. The inspection concluded without findings and no Form 483 was issued—an outcome Souza called "extremely pleasing" given the programs' complexity (earnings call, 2026-08-06).
Pipeline Setbacks and Adjustments
Not all news was positive. The POWER1 study of vormatrigine in focal onset seizures missed its primary endpoint of seizure frequency reduction, though it met a key secondary endpoint on responder rates. Souza acknowledged "our dose and a few elements of our design were not matched to the question we are asking," calling them "design problems and therefore, fixable" (earnings call, 2026-08-06). The company plans to amend and restart POWER2 and POWER3 studies by fourth quarter 2026.
On the financial side, second quarter operating expenses reached $96.9 million, up from $76 million in the prior-year period, with operating cash burn of $78 million versus $55 million. CFO Tim Kelly said the company ended the quarter with $1.4 billion in cash and equivalents, sufficient to support operations into 2028 (earnings call, 2026-08-06).
Praxis also received breakthrough therapy designation for elsunersen in SCN2A developmental and epileptic encephalopathy, marking the company's third such designation since July 2025.
Souza indicated the company would not provide further regulatory updates on either NDA until the action dates, asking investors to "read our silence between now and January as discipline rather than a signal of any kind" (earnings call, 2026-08-06).
This article was generated by MarginX from the earnings call on 2026-08-06. It is not investment advice.